Protara Therapeutics Files 8-K

Ticker: TARA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1359931

Protara Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyProtara Therapeutics, Inc. (TARA)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.001, $6.25, $6.249, $102.7 m
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, regulatory-disclosure

TL;DR

Protara Therapeutics filed an 8-K on Jan 13, 2025, covering various corporate events and financials.

AI Summary

Protara Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on events including Regulation FD disclosures, other events, and financial statements. The company, formerly known as ArTara Therapeutics, Inc. and Proteon Therapeutics Inc., is headquartered in New York, NY.

Why It Matters

This filing provides an update on Protara Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant corporate events but doesn't inherently signal high risk.

Key Players & Entities

  • Protara Therapeutics, Inc. (company) — Registrant
  • ArTara Therapeutics, Inc. (company) — Former Company Name
  • Proteon Therapeutics Inc (company) — Former Company Name
  • January 13, 2025 (date) — Date of Report
  • 345 Park Avenue South Third Floor New York , NY 10010 (address) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing for Protara Therapeutics, Inc.?

The 8-K filing serves to report on significant corporate events, including Regulation FD disclosures, other events, and financial statements and exhibits, as of January 13, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 13, 2025.

What were Protara Therapeutics, Inc.'s previous names?

Protara Therapeutics, Inc. was formerly known as ArTara Therapeutics, Inc. and Proteon Therapeutics Inc.

Where are Protara Therapeutics, Inc.'s principal executive offices located?

Protara Therapeutics, Inc.'s principal executive offices are located at 345 Park Avenue South, Third Floor, New York, NY 10010.

Under which section of the Securities Exchange Act of 1934 is this Current Report filed?

This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 1,230 words · 5 min read · ~4 pages · Grade level 11.4 · Accepted 2025-01-13 16:34:33

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share TARA The Nasdaq Capital M
  • $6.25 — price to the public in the Offering was $6.25 per share of Common Stock and $6.249 pe
  • $6.249 — was $6.25 per share of Common Stock and $6.249 per Pre-Funded Warrant, which was the p
  • $102.7 m — ption, are expected to be approximately $102.7 million, before deducting fees to the und

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 Protara Therapeutics, Inc. By: /s/ Patrick Fabbio Patrick Fabbio Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.